TY - JOUR
T1 - The extended clinical phenotype of 64 patients with dedicator of cytokinesis 8 deficiency
AU - Engelhardt, Karin R.
AU - Gertz, Michael E.
AU - Keles, Sevgi
AU - Schäffer, Alejandro A.
AU - Sigmund, Elena C.
AU - Glocker, Cristina
AU - Saghafi, Shiva
AU - Pourpak, Zahra
AU - Ceja, Ruben
AU - Sassi, Atfa
AU - Graham, Laura E.
AU - Massaad, Michel J.
AU - Mellouli, Fethi
AU - Ben-Mustapha, Imen
AU - Khemiri, Monia
AU - Kilic, Sara Sebnem
AU - Etzioni, Amos
AU - Freeman, Alexandra F.
AU - Thiel, Jens
AU - Schulze, Ilka
AU - Al-Herz, Waleed
AU - Metin, Ayse
AU - Sanal, Özden
AU - Tezcan, Ilhan
AU - Yeganeh, Mehdi
AU - Niehues, Tim
AU - Dueckers, Gregor
AU - Weinspach, Sebastian
AU - Patiroglu, Turkan
AU - Unal, Ekrem
AU - Dasouki, Majed
AU - Yilmaz, Mustafa
AU - Genel, Ferah
AU - Aytekin, Caner
AU - Kutukculer, Necil
AU - Somer, Ayper
AU - Kilic, Mehmet
AU - Reisli, Ismail
AU - Camcioglu, Yildiz
AU - Gennery, Andrew R.
AU - Cant, Andrew J.
AU - Jones, Alison
AU - Gaspar, Bobby H.
AU - Arkwright, Peter D.
AU - Pietrogrande, Maria C.
AU - Baz, Zeina
AU - Al-Tamemi, Salem
AU - Lougaris, Vassilios
AU - Lefranc, Gerard
AU - Megarbane, Andre
AU - Boutros, Jeannette
AU - Galal, Nermeen
AU - Bejaoui, Mohamed
AU - Barbouche, Mohamed Ridha
AU - Geha, Raif S.
AU - Chatila, Talal A.
AU - Grimbacher, Bodo
N1 - Funding Information:
Disclosure of potential conflict of interest: K. R. Engelhardt has received research support from BMBF (BMBF 01EO1303 ) and the European Union (EU; MEXT-CT-2006-042316-PIAID). E. M. Gertz and Alejandro A. Schäffer are employed by the National Institutes of Health (NIH). R. Ceja is employed by Children's Hospital Boston. I. Schulze has received lecture fees from CSL Behring and Octapharma. T. Niehues has received lecture fees from CSL Behring, Infectopharma, and Novartis. M. Dasouki has received research support from Genzyme Corporation and Amicus Therapeutics . A. Jones has received lecture fees and support for attending meetings from CSL Behring. M.-R. Barbouche is employed by the Ministry of Health of Tunisia. R. S. Geha is employed by Boston Children's Hospital, has received research support from the NIH ( 5R01AI100315 ), and received grant support from the Dubai-Harvard Foundation for Medical Research. T. A. Chatila has received research support from the NIH ( 5R01AI065617 and 1R21AI087627 ). B. Grimbacher has received research support from BMBF (BMBF 01EO1303 ), the EU (MEXT-CT-2006-042316-PIAID), and Helmholtz (DZIF 8000805-3 ); is employed by UCL and UKL-FR; and has received lecture fees from CSL, Baxter, and Biotest. The rest of the authors declare that they have no relevant conflicts of interest.
Funding Information:
Supported by the German Federal Ministry of Education and Research ( BMBF 01EO1303 ). The research was funded in part by the European Community's 7th Framework Programmes FP7/2007-2013 under grant agreement Health-F5-2008-223292 (Euro Gene Scan), by a Marie Curie Excellence Grant (to B.G.; MEXT-CT-2006-042316-PIAID), and by National Institutes of Health grants 5R01AI065617 and 1R21AI087627 (to T.A.C.). This research was supported in part by a grant from the Scientific and Technological Research Council of Turkey (Tubitak, grant no. 1059B191300622 ). This research was supported in part by the Intramural Research program of the National Institutes of Health , NLM , and NIAID .
Publisher Copyright:
© 2015 American Academy of Allergy, Asthma & Immunology.
PY - 2015/8/1
Y1 - 2015/8/1
N2 - Background Mutations in dedicator of cytokinesis 8 (DOCK8) cause a combined immunodeficiency (CID) also classified as autosomal recessive (AR) hyper-IgE syndrome (HIES). Recognizing patients with CID/HIES is of clinical importance because of the difference in prognosis and management. Objectives We sought to define the clinical features that distinguish DOCK8 deficiency from other forms of HIES and CIDs, study the mutational spectrum of DOCK8 deficiency, and report on the frequency of specific clinical findings. Methods Eighty-two patients from 60 families with CID and the phenotype of AR-HIES with (64 patients) and without (18 patients) DOCK8 mutations were studied. Support vector machines were used to compare clinical data from 35 patients with DOCK8 deficiency with those from 10 patients with AR-HIES without a DOCK8 mutation and 64 patients with signal transducer and activator of transcription 3 (STAT3) mutations. Results DOCK8-deficient patients had median IgE levels of 5201 IU, high eosinophil levels of usually at least 800/μL (92% of patients), and low IgM levels (62%). About 20% of patients were lymphopenic, mainly because of low CD4+ and CD8+ T-cell counts. Fewer than half of the patients tested produced normal specific antibody responses to recall antigens. Bacterial (84%), viral (78%), and fungal (70%) infections were frequently observed. Skin abscesses (60%) and allergies (73%) were common clinical problems. In contrast to STAT3 deficiency, there were few pneumatoceles, bone fractures, and teething problems. Mortality was high (34%). A combination of 5 clinical features was helpful in distinguishing patients with DOCK8 mutations from those with STAT3 mutations. Conclusions DOCK8 deficiency is likely in patients with severe viral infections, allergies, and/or low IgM levels who have a diagnosis of HIES plus hypereosinophilia and upper respiratory tract infections in the absence of parenchymal lung abnormalities, retained primary teeth, and minimal trauma fractures.
AB - Background Mutations in dedicator of cytokinesis 8 (DOCK8) cause a combined immunodeficiency (CID) also classified as autosomal recessive (AR) hyper-IgE syndrome (HIES). Recognizing patients with CID/HIES is of clinical importance because of the difference in prognosis and management. Objectives We sought to define the clinical features that distinguish DOCK8 deficiency from other forms of HIES and CIDs, study the mutational spectrum of DOCK8 deficiency, and report on the frequency of specific clinical findings. Methods Eighty-two patients from 60 families with CID and the phenotype of AR-HIES with (64 patients) and without (18 patients) DOCK8 mutations were studied. Support vector machines were used to compare clinical data from 35 patients with DOCK8 deficiency with those from 10 patients with AR-HIES without a DOCK8 mutation and 64 patients with signal transducer and activator of transcription 3 (STAT3) mutations. Results DOCK8-deficient patients had median IgE levels of 5201 IU, high eosinophil levels of usually at least 800/μL (92% of patients), and low IgM levels (62%). About 20% of patients were lymphopenic, mainly because of low CD4+ and CD8+ T-cell counts. Fewer than half of the patients tested produced normal specific antibody responses to recall antigens. Bacterial (84%), viral (78%), and fungal (70%) infections were frequently observed. Skin abscesses (60%) and allergies (73%) were common clinical problems. In contrast to STAT3 deficiency, there were few pneumatoceles, bone fractures, and teething problems. Mortality was high (34%). A combination of 5 clinical features was helpful in distinguishing patients with DOCK8 mutations from those with STAT3 mutations. Conclusions DOCK8 deficiency is likely in patients with severe viral infections, allergies, and/or low IgM levels who have a diagnosis of HIES plus hypereosinophilia and upper respiratory tract infections in the absence of parenchymal lung abnormalities, retained primary teeth, and minimal trauma fractures.
KW - Molluscum contagiosum
KW - Primary combined immunodeficiency
KW - autosomal recessive hyper-IgE syndrome
KW - dedicator of cytokinesis 8
KW - hyper-IgE syndrome
KW - signal transducer and activator of transcription 3
UR - http://www.scopus.com/inward/record.url?scp=84938738886&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84938738886&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2014.12.1945
DO - 10.1016/j.jaci.2014.12.1945
M3 - Article
C2 - 25724123
AN - SCOPUS:84938738886
SN - 0091-6749
VL - 136
SP - 402
EP - 412
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 2
ER -